Premium
Angioimmunoblastic lymphadenopathy long‐term follow‐up study
Author(s) -
Pangalis Gerassimos A.,
Moran Edgar M.,
Nathwani Bharat N.,
Zelman Ronald J.,
Kim Hun,
Rappaport Henry
Publication year - 1983
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19830715)52:2<318::aid-cncr2820520221>3.0.co;2-g
Subject(s) - medicine , lymphocytopenia , prednisone , surgery , lymphoma , pneumonia , chemotherapy , gastroenterology , lymphocyte
The clinical course of 41 previously reported patients with angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) on whom follow‐up information has been obtained for five or more years is described. Of the 41 patients, 27 achieved a complete remission (CR). The durations of the CR ranged from two to 214 months, with a median of 48 months. Nine of these 27 complete responders are still alive and well without evidence of disease, whereas the remaining 18 patients have died of pneumonia, septicemia, immunoblastic lymphoma, or unrelated causes. These 27 patients had a significantly longer median survival (51 mos) than did the 14 patients who had partial or no response (9 mos) ( P = 0.0006). Only two of these 14 patients who did not initially achieve a CR are alive (survivals, 66 months and 70 months). There was a trend suggesting that patients who received combination chemotherapy which included prednisone had a slightly longer survival than did the remaining patients ( P = 0.087). Lymphocytopenia was evident in a higher proportion of dead patients than in those who remained alive ( P = 0.089). Cancer 52:318‐321, 1983.